06.11.26 -- AI And Data Pull CDMOs Into Pharma's Commercial Strategy

A fully integrated single‑site model unifies development, manufacturing, formulation, fill‑finish, and quality oversight to reduce handoff risk and speed progression from API to sterile drug product.

As capacity expands and capabilities mature, CDMOs with global scale and advanced injectable expertise are becoming critical partners for bringing complex sterile drug products to market.

Developing new delivery routes is essential for creating more effective treatments. This enables new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.

At TIDES USA 2026, experts discuss how formulation science, stability strategies, and advanced analytics help reduce CMC risk and enable development of peptide and nucleic acid therapeutics.

Bispecific antibodies combine two antigen-binding sites to enhance efficacy and safety. Their design requires structural strategy, MOA-based evaluation, and screening for optimal therapeutic performance.

Automated visual inspection (AVI) combines robotics, precision imaging, and sophisticated defect-recognition software to provide a solution for expanding pipelines and rises in production volumes.

ADC manufacturing requires specialized expertise, single‑use systems, precise filtration, aseptic filling, and integrated lyophilization to ensure stability, safety, and consistent clinical‑grade production.

Gain expert insights on mitigating risks in global pharmaceutical manufacturing by learning from Joon Chang and Tracey Partington’s decades of industry experience.

DSP failures kill commercialization timelines. Learn how integrated harvest, filtration, and purification infrastructure protects product stability at scale.

Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety.

High-throughput screens hold insights beyond individual hits. Examine a broader view of screening data that reveals structure–function patterns to guide smarter compound prioritization.

Learn how an integrated developability and immunosafety toolbox can help de-risk multi-specific antibody development, improve candidate selection, and accelerate complex biologics toward the clinic.

ADCs require integrated, early-stage analytics to manage complex interactions among components, enabling better characterization, reduced development risk, and faster progression.